Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.54
+1.7%
$0.60
$0.16
$0.82
$578.05M0.251.25 million shs149,323 shs
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$3.65
$3.65
$2.76
$6.65
$381.02M0.93.76 million shsN/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$6.87
+0.2%
$6.33
$4.95
$12.83
$491.58M0.94709,726 shs49,993 shs
Zomedica Corp. stock logo
ZOM
Zomedica
$0.12
$0.09
$0.16
$95.35M1.034.69 million shs790,936 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-5.09%-1.12%-28.44%+29.86%+166.86%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00%0.00%0.00%0.00%+0.41%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
+3.63%-0.15%+11.93%+11.75%-26.58%
Zomedica Corp. stock logo
ZOM
Zomedica
0.00%0.00%0.00%0.00%-34.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.5134 of 5 stars
0.03.00.00.02.50.80.0
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.7144 of 5 stars
3.10.00.04.70.01.70.6
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
1.9974 of 5 stars
0.03.00.00.01.30.83.1
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.13
Hold$8.45131.51% Upside
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
0.00
N/AN/AN/A
Zomedica Corp. stock logo
ZOM
Zomedica
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$84.04M6.88$0.02 per share32.62$0.05 per share10.80
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$234.04M1.63N/AN/A($1.73) per share-2.11
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$138.72M3.54$0.87 per share7.90$3.02 per share2.27
Zomedica Corp. stock logo
ZOM
Zomedica
$25.19M0.00N/AN/A$0.24 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-$4.32MN/A0.00N/A-5.13%3.96%2.13%8/14/2025 (Estimated)
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$59.21M$0.6710.275.49N/A40.30%25.21%22.05%7/30/2025 (Estimated)
Zomedica Corp. stock logo
ZOM
Zomedica
-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/A

Latest ZOM, RVNC, SIGA, and ELTP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/30/2025Q4 2025
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/A$0.01N/A$0.02N/A$32.00 million
5/8/2025Q1 2025
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A-$0.01N/A-$0.01N/A$7.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/AN/AN/AN/AN/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/AN/AN/AN/AN/A
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.08
4.88
3.50
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/A
4.12
3.05
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A
8.40
6.28
Zomedica Corp. stock logo
ZOM
Zomedica
N/A
10.82
10.15

Institutional Ownership

CompanyInstitutional Ownership
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
97.70%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
55.40%
Zomedica Corp. stock logo
ZOM
Zomedica
8.95%

Insider Ownership

CompanyInsider Ownership
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
14.42%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
5.10%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
1.95%
Zomedica Corp. stock logo
ZOM
Zomedica
4.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
401.07 billion916.45 millionNot Optionable
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
500104.39 million99.07 millionOptionable
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
4071.44 million70.05 millionOptionable
Zomedica Corp. stock logo
ZOM
Zomedica
50979.95 million938.89 millionNot Optionable

Recent News About These Companies

15 Cheapest Stocks Insiders Are Buying In March
Q4 2024 Zomedica Corp Earnings Call
Zomedica Corp. (ZOMDF) Q4 2024 Earnings Call Transcript
Zomedica (ZOMDF) Gets a Buy from Noble Financial
Zomedica Corp.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.54 +0.01 (+1.66%)
As of 10:29 AM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Revance Therapeutics stock logo

Revance Therapeutics NASDAQ:RVNC

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Siga Technologies stock logo

Siga Technologies NASDAQ:SIGA

$6.86 +0.02 (+0.22%)
As of 11:16 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Zomedica stock logo

Zomedica NYSEAMERICAN:ZOM

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.